Cancer as a mitochondrial metabolic disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic framework based on preclinical nuclear-cytoplasm transfer experiments without original human clinical data.
PubMed 26217661 · doi:10.3389/fcell.2015.00043
What was done
The author reviewed evidence from nuclear-cytoplasm transfer experiments to evaluate the origin of cancer, comparing Otto Warburg's mitochondrial metabolic theory with the standard somatic mutation theory.
What was found
The abstract reports no numerical data or specific trial metrics. It concludes conceptually that nuclear-cytoplasm transfer findings are difficult to reconcile with the somatic mutation theory and instead support the model of cancer as a mitochondrial metabolic disease.
Why it matters
It provides a mechanistic argument challenging the nuclear mutation paradigm of oncogenesis, advocating for therapeutic and theoretical focus on mitochondrial metabolism.
Limits
The abstract describes a narrative theoretical review lacking quantitative data, human clinical outcomes, explicit search methods, or a systematic appraisal of counter-evidence.
Cited by
- supports Nuclear transfer experiments show that normal cytoplasm/mitochondria suppress tumorigenicity even in the presence of an abnormal cancer nucleus, challenging the somatic mutation theory.